CFTR and cystic fibrosis: Currently, at least 92% of people with CF are either receiving or eligible for CFTR-directed modulator therapies, and the majority of them (76%) were treated with elexacaftor–tezacaftor–ivacaftor (ETI, Trikafta®) per the 2024 CF Foundation Patient Registry Report [1].